Skye Bioscience (NASDAQ:SKYE) Issues Quarterly Earnings Results

Skye Bioscience (NASDAQ:SKYE – Get Free Report) announced its quarterly earnings results on Friday. The company reported $0.01 earnings per share for the quarter, FiscalAI reports.

Skye Bioscience Stock Up 0.9%

Skye Bioscience stock traded up $0.01 during midday trading on Friday, reaching $1.09. The stock had a trading volume of 65,157 shares, compared to its average volume of 118,122. Skye Bioscience has a 52-week low of $0.50 and a 52-week high of $11.68. The firm has a market cap of $4.83 million, a price-to-earnings ratio of -0.11 and a beta of 3.13. The company has a fifty day moving average of $1.55 and a 200 day moving average of $4.52.

Insider Activity

In related news, Director Andrew J. Schwab sold 119,379 shares of Skye Bioscience stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $1.61, for a total transaction of $192,200.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder 5Am Partners Vii, Llc sold 119,379 shares of the business’s stock in a transaction dated Wednesday, September 23rd. The shares were sold at an average price of $1.61, for a total transaction of $192,200.19. The SEC filing for this sale provides additional information. In the last three months, insiders sold 457,900 shares of company stock valued at $889,198. 6.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Skye Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Check Out Our Latest Stock Analysis on Skye Bioscience

Skye Bioscience Company Profile

(Get Free Report)

Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that modulate the endocannabinoid system, a network involved in metabolism, inflammation and immune regulation. The company is based in San Diego, California, and develops drug candidates for conditions in which endocannabinoid signaling may contribute to disease. Skye’s lead program is nimacimab, an investigational monoclonal antibody designed to inhibit the cannabinoid 1 (CB1) receptor outside the central nervous system.

Read More

Earnings History for Skye Bioscience (NASDAQ:SKYE)

Receive News & Ratings for Skye Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Skye Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.